로딩 중…
지수 로딩 중…
DAEWOONG CO.,LTD
003090· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩15,710+3.97%
2026-11-02
Financials
Valuation Metrics
DAEWOONG CO.,LTD's Market Cap is ₩9134B. At end of 2025 it was ₩1.3T. Ranked #309 of 2,405 in KR market (top 13%), #223 of 778 on KOSPI (top 29%), #32 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 14%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 913.41B KRW | KR#309/2,405 Sec#32/231 |
| Revenue | 2.12T KRW | KR#244/2,405 Sec#5/231 |
| Net Income | 221.65B KRW | KR#135/2,405 Sec#6/231 |
| Total Assets | 3.48T KRW | KR#217/2,405 Sec#5/231 |
| Net Assets | 1.88T KRW | KR#195/2,405 Sec#6/231 |
| Employees | 349 | KR#689/2,405 Sec#62/231 |
| Value | ||
| P/E | 4.12x | KR#286/2,405 Sec#9/231 |
| P/B | 0.49x | KR#836/2,405 Sec#36/231 |
| PEG | 0.04x | KR#309/2,405 Sec#16/231 |
| P/S | 0.43x | KR#871/2,405 Sec#37/231 |
| EV/EBITDA | 8.49x | KR#557/2,405 Sec#23/231 |
| FCF Yield | -4.07% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 11.81% | KR#492/2,405 Sec#34/231 |
| ROA | 6.37% | KR#586/2,405 Sec#46/231 |
| Op. Margin | 11.30% | KR#452/2,405 Sec#41/231 |
| Revenue Growth | 4.55% | KR#1,215/2,405 Sec#120/231 |
| Earnings Growth | 96.76% | KR#402/2,405 Sec#28/231 |
| Financial Health | ||
| Debt Ratio | 85.23% | KR#1,404/2,405 Sec#162/231 |
| Total Debt | 1.39T KRW | KR#161/2,405 Sec#2/231 |
| FCF | -37.22B KRW | KR#2,014/2,405 Sec#198/231 |
| Cash | 267.79B KRW | KR#216/2,405 Sec#5/231 |
| Current Ratio | 1.01x | KR#1,699/2,405 Sec#171/231 |
| Net Debt/EBITDA | 4.68x | KR#1,007/2,405 Sec#74/231 |
| Dividend | ||
| Div. Yield | 1.27% | KR#1,076/2,405 Sec#60/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -27.44% | KR#1,393/2,405 Sec#105/231 |
| 1M Return | 2.41% | KR#222/2,405 Sec#24/231 |
| From 52W High | -48.66% | KR#1,108/2,405 Sec#87/231 |
| 1Y MDD | -50.56% | KR#981/2,405 Sec#78/231 |
| Trading | ||
| Volume | 89,558 shares | KR#681/2,405 Sec#73/231 |
| Trading Value | 1.38B KRW | KR#509/2,405 Sec#51/231 |
| Foreign Own. | 5.02% | KR#855/2,405 Sec#76/231 |
| Per Share | ||
| EPS | 3,812 KRW | KR#281/2,405 Sec#17/231 |
| BPS | 32,291 KRW | KR#345/2,405 Sec#24/231 |
Company Info
Daewoong, established in 1961 as Daehan Vitamin Industry Co., Ltd. and listed in 1973, transitioned to a holding company through a spin-off in 2002. As the holding company of a global healthcare group, it owns 36 subsidiaries including Daewoong Pharmaceutical, engaging in pharmaceutical manufacturing and investment. Daewoong focuses on enhancing global market penetration with Fexuclue, Enavlo, and Nabota, while strengthening K-Bio's status. The company is headquartered in Seongnam, Gyeonggi Province.